|
Provectus Pharmaceuticals (PVCT) specializes in developing oncology and dermatology therapies.
Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and metastatic cancers of the liver.
The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications.
Its dermatological drug PH-10 also targets abnormal or diseased cells, with the current focus on psoriasis and atopic dermatitis. Provectus has recently completed Phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis.
Provectus is based out of Memphis, Tennessee.
COMPANY WEBSITE
PRESENTATION
December 8th, 12:00 pm - Track Four
| 
